Biologic and targeted therapeutics in vitiligo

Publication type:
Journal article
Metadata:
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Vitiligo is a long‐standing progressive autoimmune disease with depigmented macules/patches with significant psychological morbidity to the patients. From being one of the most poorly understood diseases in the past, there has been a rampant advance in determining the molecular and genetic factors influencing the disease process. More light has been shed on the complex intracellular environment and interplay between innate and adaptive immunity. Numerous cytokines and signaling pathways have been associated with disease pathogenesis in the recent past.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>The aim of this review the efficacy of biologic and targeted therapeutics in vitiligo.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A detailed literature search was conducted on databases like PubMed, COCHRANE Central, EMBASE and Google Scholar using keywords—“biologics,” “vitiligo,” “treatment,” “repigmentation,” “JAK inhibitors,”, “TNF‐ꭤ inhibitors,” and “IL17/23 inhibitors,” Relevant studies and review articles in English were analyzed in detail and report was written. This article aimed at a comprehensive review of all the biologicals and newer targeted therapeutics tried in vitiligo and their efficacy with an insight into the potential complications arising as a result of the therapy.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Most conventional vitiligo treatment modalities are restricted to generalized nonspecific immunosuppressants like topical and oral corticosteroids, calcineurin inhibitors, phototherapy, and surgical modalities. There have been reports and studies on the usage of biologicals in treating vitiligo. JAK inhibitors have shown good efficacy in vitiligo; however, it lacks substantial evidence in the form of randomized control trials. Similarly, the use of targeted therapeutics in treating vitiligo is substantiated by limited evidence and requires more randomized trials for further evidence.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>JAK inhibitors have shown promising results and good tolerability; Adjuvant phototherapy can achieve a superior response compared to monotherapy. Though TNF‐ꭤ has been tried in a few cases, it is best used if vitiligo is present in association with other chronic autoimmune diseases for which it is indicated. More in vitro studies and clinical research are required to understand the pathogenesis clearly, and therapy has to be targeted at specific pathways for a better approach toward vitiligo. Treatment aimed at induction and differentiation of melanocytes may be added to achieve faster repigmentation.</jats:p></jats:sec>
Autoren
  • Priyanka Karagaiah
  • Robert A Schwartz
  • Torello Lotti
  • Uwe Wollina
  • Stephan Grabbe
  • Mohamad Goldust
DOI
10.1111/jocd.14770
eISSN
1473-2165
ISSN
1473-2130
Ausgabe der Veröffentlichung
1
Zeitschrift
Journal of Cosmetic Dermatology
Sprache
en
Online publication date
2022
Paginierung
64 - 73
Datum der Veröffentlichung
2023
Status
Published
Herausgeber
Wiley
Herausgeber URL
http://dx.doi.org/10.1111/jocd.14770
Datum der Datenerfassung
2023
Titel
Biologic and targeted therapeutics in vitiligo
Ausgabe der Zeitschrift
22

Data source: Crossref

Other metadata sources:
Author's licence
CC-BY-NC
Autoren
  • Priyanka Karagaiah
  • Robert A Schwartz
  • Torello Lotti
  • Uwe Wollina
  • Stephan Grabbe
  • Mohamad Goldust
Hosting institution
Universitätsbibliothek Mainz
Sammlungen
  • DFG-491381577-H
Resource version
Published version
DOI
10.1111/jocd.14770
Funding acknowledgements
  • Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577
File(s) embargoed
false
Open access
true
ISSN
1473-2165
Ausgabe der Veröffentlichung
1
Zeitschrift
Journal of cosmetic dermatology
Schlüsselwörter
  • 610 Medizin
  • 610 Medical sciences
Sprache
eng
Open access status
Open Access
Paginierung
64 - 73
Datum der Veröffentlichung
2023
Public URL
https://openscience.ub.uni-mainz.de/handle/20.500.12030/8647
Herausgeber
Wiley-Blackwell
Datum der Datenerfassung
2023
Datum, an dem der Datensatz öffentlich gemacht wurde
2023
Zugang
Public
Titel
Biologic and targeted therapeutics in vitiligo
Ausgabe der Zeitschrift
22

Files

biologic_and_targeted_therape-20230124103018682.pdf

Data source: OPENSCIENCE.UB

Tools